Wiley Matthew T. - 17 Jan 2022 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role
CHIEF COMMERCIAL OFFICER
Signature
/s/ Javier Rodriguez, as Attorney-in-Fact for Mathew T. Wiley
Issuer symbol
BTAI
Transactions as of
17 Jan 2022
Net transactions value
$0
Form type
4
Filing time
19 Jan 2022, 15:19:39 UTC
Previous filing
02 Jul 2021
Next filing
16 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTAI Stock Option (Right to Buy) Award $0 +85,000 $0.000000 85,000 17 Jan 2022 Common Stock 85,000 $19.50 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of January 17, 2022 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.